Delaware was one of three states that joined together in the bid for the PROPEL Tech Hub, seeking close to $80 million to boost the region’s relevance in precision medicine.
When the EastSide Charter School community STEM facility opens in the next couple months, it will feature a new program set to train adults in biomanufacturing and basic lab functions.
AstraZeneca has recently completed a $2.4 billion deal for a California-based pharmaceutical company that gives the company a boost in next-generation cancer treatments.
Work is underway at a $150 million manufacturing center, marking a new chapter of the next National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Center.
Incyte is reportedly closing on buying 1100 N. King Street and 1100 N. French Street in downtown Wilmington as its latest stage of expansion efforts. The move will bring eventually 800 people to downtown Wilmington.
While the biopharmaceutical industry has historically been a treadmill of innocation, pharma companies are looking into new strategies while contending with growing emphasis on technology, lower prices and a highly competitive market.
The second annual Delaware DNA conference hosted by the Delaware BioScience Association drew around 320 people seeking to gain perspective on the successes and challenges in the state’s pharmaceutical industry.
